P7C3-A20

01/01/2018 - "In the present study, we investigated a more clinically relevant therapeutic window for P7C3-A20 treatment after ischemic stroke. "
01/01/2018 - "These results demonstrate that P7C3-A20 improves chronic functional and histopathological outcomes after ischemic stroke with an extended therapeutic window."
01/01/2017 - "The effectiveness of P7C3-A20 treatment on chronic histopathological and behavioral outcomes and neurogenesis after ischemic stroke has not previously been established. "
01/01/2017 - "The neuroprotective compound P7C3-A20 promotes neurogenesis and improves cognitive function after ischemic stroke."
01/01/2016 - "Neuroprotective Efficacy of an Aminopropyl Carbazole Derivative P7C3-A20 in Ischemic Stroke."

05/01/2024 - "Thus, P7C3-A20 can treat traumatic brain injury in rats by inhibiting excessive autophagy and apoptosis."
05/01/2024 - "P7C3-A20 or vehicle was injected intraperitoneally after traumatic brain injury. "
05/01/2024 - "P7C3-A20 treats traumatic brain injury in rats by inhibiting excessive autophagy and apoptosis."
12/12/2018 - "The antiapoptotic, neuroprotective compound P7C3-A20 reduces neurological deficits when administered to murine in-vivo models of traumatic brain injury. "
05/01/2024 - "Therefore, in the present study, we investigated the therapeutic effects of P7C3-A20 on traumatic brain injury and explored the putative underlying molecular mechanisms. "

01/01/2017 - "Here, a transient middle cerebral artery occlusion in rats was followed by twice daily injection of P7C3-A20 or vehicle for 7days. "
01/01/2018 - "We recently showed that the neuroprotective compound P7C3-A20 reduced brain atrophy, increased neurogenesis, and improved functional recovery when treatment was initiated immediately post-reperfusion after a 90-min middle cerebral artery occlusion (MCAO). "
01/01/2016 - "In vivo experiment, P7C3-A20 was administrated in middle cerebral artery occlusion (MCAO) rats and infarct volume was examined. "

10/01/2020 - "In HI model rats, treatment with 5 or 10 mg/kg P7C3-A20 reduced infarct volume; reversed cell loss in the cortex and hippocampus and improved motor function without causing neurotoxicity. "
01/01/2018 - "In the cerebral cortex, delayed P7C3-A20 treatment significantly increased tissue sparing 7 weeks after stroke and reduced hemispheric infarct volumes 48 h after reperfusion. "
01/01/2016 - "In vivo experiment, P7C3-A20 was administrated in middle cerebral artery occlusion (MCAO) rats and infarct volume was examined. "

01/01/2018 - "Delayed P7C3-A20 treatment significantly improved stroke-induced sensorimotor deficits in motor coordination and symmetry, as well as cognitive deficits in hippocampal-dependent spatial learning, memory retention, and working memory. "
01/01/2018 - "In the hippocampus, only immediately treated P7C3-A20 animals had a significant increase in tissue sparing compared to vehicle-treated stroke animals. "
12/01/2017 - "Corrigendum to "The neuroprotective compound P7C3-A20 promotes neurogenesis and improves cognitive function after stroke" [Exp. Neurol. "
01/01/2018 - "In the cerebral cortex, delayed P7C3-A20 treatment significantly increased tissue sparing 7 weeks after stroke and reduced hemispheric infarct volumes 48 h after reperfusion. "